Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MDH2 | P40926 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | NMT1 | P30419 | 6/20 | 0.49 |
| ▸ | NMT2 | O60551 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338576 | 0.88 | SLC16A3 (0.49) | MAOBMCL1SLC16A3MEN1KMT2A | |
| SCHEMBL30532968 | 0.86 | NMT1 (0.65) | MAOBALDH1A1HPGDSMN1; SMN2NMT1 | |
| SCHEMBL17338603 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31668736 | 0.83 | KDM4E (0.54) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL13771871 | 0.83 | MCL1 (0.48) | HPGDMCL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2400044 | 0.82 | CYP3A4 (0.48) | MAOBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1041518 | 0.80 | LMNA (0.54) | ALDH1A1HPGDSMN1; SMN2MCL1 | |
| SCHEMBL311213 | 0.79 | MEN1 (0.48) | MAOBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17338602 | 0.79 | MCL1 (0.45) | ALDH1A1HPGDMCL1MEN1KMT2A | |
| SCHEMBL30533025 | 0.78 | SRD5A2 (0.48) | MAOBALDH1A1SMN1; SMN2NMT1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | UCL BUSINESS PLC (GB) | 2018-10-02 | — | — | US | disclosed |
| EP-3145914-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL Business PLC (GB) | 2017-03-29 | — | — | EP | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| WO-2015189560-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | CBR3, AGTR1, CBR1 | MAOB 2625/4885ALDH1A1 3209/4885HPGD 1392/4885 |
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | AGTR1, CBR3, CBR1 | MAOB 2376/4885ALDH1A1 3232/4885HPGD 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.